 |
Case Study: Expanding Services
Problem
New technologies that help to improve and refine biopharmaceutical drugs emerge at an ever increasing pace. Even for large companies it is often difficult to assess advantages of one technology over another and to estimate the market potential for such technologies. | |
|
|
Approach and Solution
evalueSCIENCE chose form its pool of evalueSCIENCE Experts the international specialists in the field. The first Experts provided an indepth assessment of the different technologies and their potential market value. This asessment was subsequently reviewed and extended by a second Expert in a consecutive peer review process. On the basis of this technology assessment an IP and market analysis was conducted. The resulting report contained specific recommentations on how to proceed in utilizing these technologies.
| |
|
Case Study: New Market Entry
Problem
A Swiss Biotech Company (Dualsystems AG) was interested in entering enter a new market by adopting a new not yet commercially available technology.
| |
|
|
Approach and Solution
evalueSCIENCE chose two experts from its pool of over 50 evalueSCIENCE Experts to assess the technology, provide a rough cost calculation, investigate the potential market and to perform a small scale market survey with potential customers. The product was a final report including the expert opinion, market analysis and cost calculation. Based on the expert opinion the report expressed a clear recommendation on how to proceed. Thanks to the rapid response of the evalueSCIENCE Experts and the precise match with their area of expertise it was possible to conduct the review and write the report within 14 days over X-mas and New Year.
"I would like to thank you for the excellent work of evalueSCIENCE. The report has helped very much in our decision. Should you need a reference in the future, I would be happy to provide it" Dr. Daniel Auerbach, CEO Dualsystems AG.
| |
|
Case Study: Immunology
Problem
Our client, a venture capital company with a diverse investment portfolio, was asked to invest in a early stage company in the field of immunology. Confligating interests made a decision complicated. Furthermore, the client had no expertise to validate the scientific basis and the business concept of the investment opportunity.
| |
|
|
Approach and Solution
evalueSCIENCE conducted a Science Due Diligence (SDD). A carfully assigned evalueSCIENCE Expert, a specialist in immunology, was asked to lead the process.
In a first step one international expert was asked to review the rational of the scientific approach of the company to invest in. To avoid conflicts of interests and guarantee confidentiality the identity of the evalueSCIENCE Expert and the peers he selected was revealed to the owner on the company. All the experts signed a confidentiality agreement with evalueSCIENCE. Two of the peers discussed specific points with the company owner by phone. The first expert had to comment on the potential of a specific immune modulating molecule as a therapeutic agent. In the second step two additional experts were chosen to comment on the scientific and commercial potential of the platform technology, the company wanted to apply.
The Science Due Diligence resulted in a synposis with recomendations by the evalueSCIENCE Expert. The platform of the company was considered of interest and potential value, the pipeline that has emerged from the platform, however, was viewed as disappointing so far. Furthermore, a detailed design of the clinical trials for the candidate molecules was missing. As a result of the SDD the client decided not to invest in the company. | |
|
